Bleichmar Fonti & Auld LLP files lawsuit against Organon & Co. for securities fraud.

A lawsuit has been filed against Organon & Co. (NYSE: OGN) for potential violations of federal securities laws. The complaint alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey. Investors have until July 22, 2025, to ask the Court to be appointed to lead the case.

A lawsuit has been filed against Organon & Co. (NYSE: OGN) for potential violations of federal securities laws. The complaint alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey [1].

Organon, a global healthcare company focused on women’s health, completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions, in October 2024. The acquisition increased Organon’s debt, and the company assured investors it would maintain its dividend, which was its “#1 capital allocation priority” [1].

However, it was later revealed that Organon had shifted its capital allocation priority to focus on reducing its debt, leading to a severe cut in its dividend. On May 1, 2025, Organon announced a reset of its dividend payout from $0.28 per share to $0.02 per share. This news triggered a 27% decline in Organon's stock price, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [1].

Investors who purchased Organon securities between October 31, 2024, and April 30, 2025, may be eligible to participate in the class action lawsuit. They have until July 22, 2025, to request that the Court appoint them as lead plaintiffs [2]. The lawsuit alleges that Organon and its executives made misleading statements to investors about the company's priorities, particularly regarding capital allocation through quarterly dividends [2].

The lawsuit is being handled by leading securities law firms, including Bleichmar Fonti & Auld LLP and Levi & Korsinsky. BFA has recovered over $900 million in value from Tesla, Inc.'s Board of Directors, and $420 million from Teva Pharmaceutical Ind. Ltd. Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases [1][2].

Investors who suffered losses are encouraged to submit their information to the respective law firms. There is no cost to participate, and shareholders are not responsible for any court costs or expenses of litigation [1][2].

References:
[1] https://www.globenewswire.com/news-release/2025/07/18/3117938/0/en/OGN-SECURITIES-FRAUD-Organon-Co-NYSE-OGN-27-Stock-Drop-Triggers-Class-Action-Lawsuit-Contact-BFA-Law-by-July-22-Legal-Deadline.html
[2] https://www.morningstar.com/news/pr-newswire/20250718ny32677/levi-korsinsky-notifies-shareholders-of-organon-coogn-of-a-class-action-lawsuit-and-an-upcoming-deadline